The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects

NCT01905553 | Completed Phase 1 Results

• 1 other identifier: SPD602-113
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

To assess the effect of food on the pharmacokinetic profile of SSP-004184 compared to administration under fasted conditions.

Conditions

Healthy

Outcome Measures

Primary Outcomes (3)

• Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of SSP-004184 Under Fasted and Fed Conditions

  AUCinf is the area under the plasma concentration versus time curve from time 0 to infinity. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

  Study Periods 1 & 2: Within 30 minutes pre-dose, and Post-dose 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 48, 72 hours.

• Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measureable Concentration (AUClast) of SSP-004184 Under Fed and Fasted Conditions

  AUClast is the area under the curve from the time of dosing to the last measurable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

  Study Periods 1 & 2: Within 30 minutes pre-dose, and Post-dose 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 48, 72 hours.

• Maximum Plasma Concentration (Cmax) of SSP-004184 Under Fed and Fasted Conditions

  Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

  Study Periods 1 & 2: Within 30 minutes pre-dose, and Post-dose 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 48, 72 hours.

Study Arms (2)

SSP-004184SS (fed)

EXPERIMENTAL

21.8 mg/kg (oral capsule form) given once on Day 1 under fed conditions

Drug: SSP-004184SS

SSP-004184SS (fasted)

EXPERIMENTAL

21.8 mg/kg (oral capsule form) given once on Day 1 under fasted conditions

Drug: SSP-004184SS

Interventions

SSP-004184SS DRUG

Disodium salt

Also known as: SPD602

SSP-004184SS (fasted); SSP-004184SS (fed)

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject is considered "healthy". Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, and urinalysis.
• Serum ferritin \>20ng/mL, hemoglobin \>125g/l, and erythrocyte indices within normal range of the clinical laboratory at the Screening Visit and on Day -1: packed cell volume, mean corpuscular volume, and mean corpuscular hemoglobin concentration, or deemed not clinically significant by the investigator.
• Subject is willing to comply with any applicable contraceptive requirements of the protocol and is:
• Male, or
• Female of non-childbearing potential (defined as a female who is post-menopausal \[amenorrhea for at least 12 consecutive months\] or surgically sterile \[hysterectomy, bilateral tubal ligation, bilateral oophorectomy, or bilateral salpingectomy\]) and at least 6 weeks post-sterilization
• Non-pregnant, non-lactating female
• At least 90 days post-partum or nulliparous (females only).
• An understanding, ability, and willingness to fully comply with study procedures and restrictions.
• Ability to provide written, personally signed, and dated informed consent to participate in the study, in accordance with International Conference on Harmonisation Good Clinical Practice Guideline E6 (1996) and applicable regulations, before completing any study-related procedures.
• Ability to swallow the investigational product (multiple capsules at 1 time or consecutively 1 capsule at a time).

You may not qualify if:

• A clinically significant history or disorder detected during the medical interview/physical examination such as any cardiovascular, bronchopulmonary, gastrointestinal (eg, inflammatory bowel disease, chronic diarrhea), hepatic, biliary (including gall bladder removal), renal, hematological, endocrine, autoimmune, neurological, or psychiatric disease (including depression) or any other medical condition that is capable of altering the absorption, metabolism, or elimination of drugs; or of constituting a risk factor when taking the investigational product in the judgment of the investigator.
• Confirmed systolic blood pressure \>139mmHg or \<89mmHg, and diastolic blood pressure \>89mmHg or \<49mmHg.
• Twelve-lead ECG demonstrating QTc \>450msec at screening. If QTc exceeds 450msec, the ECG should be repeated 2 more times and the average of the 3 QTc values should be used to determine the subject's eligibility.
• Subject reports any food allergies, celiac disease, or requirements for specific diet (eg, vegan, vegetarian, low fat).
• Acute illness, as judged by the investigator, within 2 weeks of Day 1 of Treatment Period 1.
• Known or suspected intolerance or hypersensitivity to the investigational products, closely related compounds, or any of the stated ingredients.
• History of thyroid disorder that has not been stabilized on thyroid medication or treatment within 3 months of the Screening Visit.
• History of alcohol or other substance abuse within the last year.
• Routine consumption of more than 3 units of caffeine per day or subjects who experience caffeine withdrawal headaches.
• A positive screen for alcohol or drugs of abuse at the Screening Visit.
• Male subjects who consume more than 3 units of alcohol per day. Female subjects who consume more than 2 units of alcohol per day.
• A positive human immunodeficiency virus antibody screen, hepatitis B surface antigen screen, or hepatitis C virus antibody screen.
• Current use of any other medication (including over-the-counter, herbal, or homeopathic preparations) that could affect (improve or worsen) the study evaluations according to the investigator.
• Use of tobacco in any form (eg, smoking or chewing) or other nicotine-containing products in any form (eg, gum, patch) within 30 days prior to Day 1 of Treatment Period 1.
• Donation of blood or blood products (eg, plasma or platelets) within 60 days prior to Day 1 of Treatment Period 1.

Sponsors & Collaborators

• Shire: lead

Study Sites (1)

Clinical Pharmacology of Miami

Miami, Florida, 33014, United States

Location

Results Point of Contact

• Title: Study Director
• Organization: Shire

ClinicalTransparency@shire.com

+1 866 842 5335

Study Officials

• Study Director

  Takeda

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 18, 2013
• First Posted: July 23, 2013
• Study Start: August 27, 2013
• Primary Completion: September 24, 2013
• Study Completion: September 24, 2013
• Last Updated: June 24, 2021
• Results First Posted: December 24, 2014

Record last verified: 2021-06

Locations

US (1)